Format

Send to

Choose Destination
World J Gastroenterol. 2007 Apr 14;13(14):2089-93.

Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue?

Author information

1
Department of Gastro-enterology, Univerisity Medical Centre Utrecht, Utrecht, The Netherlands.

Abstract

AIM:

To study the effect of infliximab on fatigue in relation to cytokine levels in Crohn's disease (CD) patients.

METHODS:

Fourteen CD patients were blinded for treatment and received placebo at baseline, and infliximab 2 wk later, with a follow-up of 4 wk. Blood samples were drawn on a regular basis, and questionnaires on fatigue, depression, quality of life, and clinical disease activity were completed at regular intervals.

RESULTS:

After placebo infusion, fatigue scores decreased within 3 d (3.5 points +/- 1.1, P <or= 0.01), but returned to baseline values 14 d after this infusion. The drop of fatigue scores following infliximab infusion sustained until the end of the study (3.8 points +/- 1.4, P <or= 0.05). Quality of life was increased at the end of the study compared to baseline values (138.6 +/- 9.4 vs 179.4 +/- 6.7; P <or= 0.005), whereas depression scores were decreased (20.4 +/- 9.4 vs 11.3 +/- 2.2; P <or= 0.01). No correlation between the severity of fatigue and the level of cytokines was observed.

CONCLUSION:

The reduction of fatigue after infliximab infusion is subjective to a placebo effect. The effect of infliximab on fatigue, however, persists while the placebo effect disappears after a short period of time. A clear role of cytokines could not be substantiated.

PMID:
17465453
PMCID:
PMC4319130
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center